
The Lenacapavir Partnership and the Evolution of U.S. Foreign Assistance | The Futures Summit
In September 2025, the U.S. Department of State, Gilead Sciences, and the Global Fund to Fight AIDS, Tuberculosis and Malaria announced a novel partnership to procure and deliver lenacapavir—a groundbreaking twice-yearly injectable pre-exposure prophylaxis (PrEP) for HIV prevention—to up to two million people over next three years.
On Tuesday, April 14, the leadership of these three entities convened to discuss the partnership now that doses have begun to arrive in country and have been delivered. Katherine E. Bliss, Director of Immunizations and Health Systems Resilience and Senior Fellow…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.